Stimuli‐Responsive Nanoplatforms for Precision Intervention in Rheumatoid Arthritis
WIREs Nanomedicine and Nanobiotechnology · 2026-07 · 18 (4)
DOI: 10.1002/wnan.70073 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift WIREs Nanomedicine and Nanobiotechnology, online erschienen am 06.08.2026. Verfasst von Ao Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy and State Key Laboratory of Mechanism and Quality Research in Chinese Medicine, Macau University of Science and Technology, Macao,…. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Precision Medicine, Nanoparticles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 252 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Macau Science and Technology Development Fund, National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province.
Abstract (Originalsprache)
Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by persistent synovial inflammation and progressive joint destruction. While conventional pharmacotherapies form the cornerstone of RA management, their efficacy is often limited by suboptimal therapeutic outcomes and severe systemic toxicity. In this context, stimuli‐responsive nanoplatforms (SR‐NPs) have emerged as a promising approach for precision treatment of RA, enabling on‐demand drug release triggered by disease‐specific endogenous (e.g., pH, ROS, enzymes, GSH, hypoxia) or exogenous (e.g., light, ultrasound, magnetic fields, heat) cues. This review provides a systematic overview of the cutting‐edge applications of SR‐NPs, categorizing them into endogenous (single‐ and multi‐stimuli), exogenous (single‐ and multi‐stimuli), and hybrid endogenous‐exogenous (e.g., ROS/pH/light, GSH/heat) responsive systems. We critically evaluate the design principles, targeting mechanisms, therapeutic payloads, and performance of each category in preclinical RA models. Our analysis reveals that endogenous systems leverage the pathological microenvironment for disease‐dependent actuation, exogenous platforms offer tunable spatiotemporal control, while hybrid designs represent an emerging trend toward synergistic and programmable precision. Despite promising advances in enhanced joint retention and effective inflammation suppression, key challenges concerning stimulus heterogeneity, long‐term biocompatibility, and clinical translation remain to be addressed. Taken together, this work underscores the evolution of SR‐NPs into intelligent and multifaceted therapeutics, thereby providing a potential framework for personalized RA management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- School of Pharmacy and State Key Laboratory of Mechanism and Quality Research in Chinese Medicine, Macau University of Science and Technology, Macao, China.
ORCID-Profile: Ao Li, Qi Chen, Hui Guo, Xiaolin Wang
Förderung
- Macau Science and Technology Development Fund
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- Shenzhen Science and Technology Innovation Commission
- Science, Technology and Innovation Commission of Shenzhen Municipality
Zitieren
APA
Li, A., Chen, Q., Zhong, J., Meng, S., Xiao, Y., Zhong, A., Zhang, Y., Zhang, X., Guo, H., & Wang, X. (2026). Stimuli‐Responsive Nanoplatforms for Precision Intervention in Rheumatoid Arthritis. WIREs Nanomedicine and Nanobiotechnology, 18(4). https://doi.org/10.1002/wnan.70073
Vancouver
Li A, Chen Q, Zhong J, Meng S, Xiao Y, Zhong A, et al. Stimuli‐Responsive Nanoplatforms for Precision Intervention in Rheumatoid Arthritis. WIREs Nanomedicine and Nanobiotechnology. 2026;18(4). doi:10.1002/wnan.70073
BibTeX
@article{Li2026,
author = {Li, Ao and Chen, Qi and Zhong, Jingyi and Meng, Shiyu and Xiao, Yi and Zhong, Aoxue and Zhang, Yuying and Zhang, Xican and Guo, Hui and Wang, Xiaolin},
title = {Stimuli‐Responsive Nanoplatforms for Precision Intervention in Rheumatoid Arthritis},
journal = {WIREs Nanomedicine and Nanobiotechnology},
year = {2026},
volume = {18},
number = {4},
doi = {10.1002/wnan.70073}
}
EUVIMED